CREBBP and breast cancer: To explore the transcriptional events underlying the phenotypic response to CREBBP/EP300 acetyltransferase inhibition, we carried out RNA sequencing analysis of three breast cancer cell lines (MCF7, T47D, and ZR751) treated with CPI-1612 alone or in combination with Fulvestrant.